$MEDS SEC Filings

This Second Amended and Restated Letter of Intent (this “LOI”) sets forth our current proposal with regard to the proposed combination (the “Transaction”) of DataMEDS AI, Inc., a reporting public company incorporated in Delaware and f/k/...

Tampa, Fla. – Tuesday, October 20, 2026 – DataMeds AI, Inc. (NASDAQ: MEDS) (“DataMeds AI,” “DataMEDS SI,” “DataMEDS,” or the “Company”), a healthcare company leveraging its Health IT and physical infrastructure together with its super in...

On October 13, 2026 (the “Effective Date”), DataMeds AI, Inc. (“DataMeds” or the “Company”) entered into an Intellectual Property License and Product and Services Agreement (the “IP License Agreement”) with REBOOT Health AI, Inc., a Dela...

As of October 13, 2026, DataMEDS AI, Inc. (the “Company”) confirms that its stockholders’ equity is greater than $2,500,000. The transactions below resulted in the increase to the Company’s stockholders’ equity.

On September 11, 2026, DataMEDS AI, Inc. (the “Company”) entered into a settlement agreement and release (the “Agreement”) with Brian Norton, individually and as Seller Representative (“Norton”), Tony Madsen, Mark DiSiena, T. Scott Madse...

THIS Stock Purchase Agreement (the “Agreement”) is entered into as of September 11, 2026, by and between DataMeds AI, Inc. (fka Wellgistics Health, Inc.) (NASDAQ: MEDS), a Delaware corporation (“Buyer”), and Axe Compute Inc., a Delaware ...

Received 100,000 shares by exercise ($500) · Acquired 100,000 Warrant (In/At-money Exercise)

Received 100,000 shares by exercise ($500) · Acquired 100,000 Warrant (In/At-money Exercise)

Received 5,000,000 shares as a grant or award ($1M) · Granted 5,000,000 Warrant ($500)